Hao Deng

Department of Anesthesiology, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston USA.

2 papers in the library · 3 citations · publishing 2025

Papers

Outcomes of Sedative Hypnotic Agents Used for Endotracheal Intubation in Critically Ill Adults: A Systematic Review with Exploratory Meta-Analysis.

Journal of intensive care medicine May 14, 2025 Nathan J Smischney, George Williams, Craig S Jabaley et al. 2 citations

Among critically ill adults undergoing endotracheal intubation, acute cardiovascular dysfunction (hemodynamic instability or cardiac arrest) occurred at similar rates with etomidate and ketamine but was more frequent with propofol than with non-propofol sedation. Exploratory meta-analysis showed no statistically significant difference between etomidate and ketamine (odds ratio 1.05) or between etomidate and propofol (odds ratio 0.91). However, etomidate was associated with lower survival to hospital discharge compared to ketamine (odds ratio 0.76). Limited data for other outcomes such as acute kidney injury, delirium, or length of stay revealed no clear differences among the sedative agents.

DOI: 10.1177/08850666251337702 Full text Critically ill Endotracheal intubation Patient outcomes Intubation procedures +3

Effectiveness and safety of ofatumumab in treatment-naive and oral DMT-switched multiple sclerosis patients: a multicenter observational study in China.

Multiple sclerosis and related disorders November 1, 2025 Yang Yang, Xinyi Duan, Jing Wang et al. 1 citation

Ofatumumab, a fully humanized anti-CD20 antibody, reduced disease activity and disability progression in Chinese patients with relapsing multiple sclerosis. Among 38 treatment-naïve patients, the annualized relapse rate fell from 0.27 to 0.05, and the median disability score dropped from 2.50 to 2.00 after 12 months. Among 59 patients who switched from oral therapies (teriflunomide, siponimod, fingolimod, dimethyl fumarate) due to disease progression, relapse, or MRI activity, the relapse rate decreased from 0.45 to 0.08 and disability scores improved from 2.00 to 1.00. No new MRI lesions, relapses, or serious adverse events occurred in either group.

DOI: 10.1016/j.msard.2025.106827 Full text Multiple sclerosis Ofatumumab Real-world data Switch +2